Ignite Creation Date:
2025-12-25 @ 12:24 AM
Ignite Modification Date:
2026-01-08 @ 4:46 PM
Study NCT ID:
NCT05528458
Status:
RECRUITING
Last Update Posted:
2024-04-23
First Post:
2022-08-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Sponsor:
Samsung Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-26
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-08-30
First Submit QC Date:
None
Study First Post Date:
2022-09-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-21
Last Update Post Date:
2024-04-23
Last Update Post Date Type:
ACTUAL